Keivanidou Anastasia, Arnaoutoglou Christos, Krommydas Argyrios, Papanikolaou Georgios, Tsiptses Konstantinos, Chrisopoulos Charalampos, Kirpizidis Christos
Department of Cardiology, 2nd IKA "Panagia" Hospital, Thessaloniki, Greece.
Cardiol J. 2009;16(2):172-4.
We report one case of cardiac arrest related to ciprofloxacin administration. One female patient (aged 70 years old) developed a marked QTc prolongation (QTc = 0.62 s) within 24 hours of ciprofloxacin administration, with documented torsades de pointes and recurrent syncope that required defibrillation. The patient was under amiodarone and sotalol therapy for atrial fibrillation, with no obvious QT prolongation prior to ciprofloxacin therapy. QT prolongation and subsequent torsades de pointes appeared only after initiation of ciprofloxacin and normalized after drug discontinuation. Even though ciprofloxacin is thought to be safer than other agents in its class, it may cause QT prolongation and torsades de pointes, particularly in high risk patients with predisposing factors. Prolongation of the QT interval related to the effect of fluoroquinolones on rapid potassium channels (IKr) may result on potentially serious proarrhythmic effect, leading to torsades de pointes.
我们报告1例与环丙沙星给药相关的心脏骤停病例。1名70岁女性患者在给予环丙沙星后24小时内出现明显的QTc延长(QTc = 0.62秒),记录到尖端扭转型室速和反复晕厥,需要进行除颤。该患者正在接受胺碘酮和索他洛尔治疗心房颤动,在环丙沙星治疗前无明显QT延长。QT延长及随后的尖端扭转型室速仅在开始使用环丙沙星后出现,停药后恢复正常。尽管环丙沙星被认为比同类其他药物更安全,但它可能导致QT延长和尖端扭转型室速,尤其是在有易感因素的高危患者中。与氟喹诺酮类药物对快速钾通道(IKr)的作用相关的QT间期延长可能导致潜在的严重心律失常效应,从而引发尖端扭转型室速。